VALENCIA, Calif., April 17 /PRNewswire-FirstCall/ -- MannKind Corporation , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will be presenting at the UBS Global Specialty Pharmaceutical Conference on Monday, April 24, 2006 at 2:00 p.m. Eastern Time (11:00 a.m. PT). This conference will be held at The Grand Hyatt in New York City.
Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company’s website at www.mannkindcorp.com. A replay of the presentation will be available for 14 days.
About MannKind Corporation
MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead investigational product candidate, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.
MannKind Corporation
CONTACT: Dick Anderson, Chief Financial Officer of MannKind Corporation,+1-661-775-5302, danderson@mannkindcorp.com; or Investor Relations, JulieHuang of Financial Dynamics, +1-212-850-5628, mnkd@fd-us.com, for MannKindCorporation
Web site: http://www.mannkindcorp.com/
